Kornimate/medical-research-clean huggingface dataset:
forward head posture and myogenic tmd association in smartphone overuse

Conditions: Temporomandibular Disorder

Summary: the goal of this observational study is to determine the correlation between forward head posture and myogenic temporomandibular disorder, pain pressure threshold and endurance of masticatory and neck muscles in addicted smart phone users. the main question it aims to answer is: • what is the correlation between forward head posture and myogenic temporomandibular disorder, pain pressure threshold and endurance of masticatory and neck muscles in addicted smart phone users?

temporomandibular joint (tmj) and cervical spine are closely related to each other due to their anatomical, mechanical and neurophysiological relationships. that's why pain and dysfunction in the cervical spine can be observed in patients with temporomandibular disorders (tmd) who may suffer from clinical problems in the masticatory muscles, the temporomandibular joint and other associated structures. millions of people worldwide use their smartphone devices excessively. prevalence of smartphone addiction among egyptian university students was 62.4% revealing that females had a higher addiction than men. this excessive use where subjects downwardly flex their neck to enable them to look at the screen, affects head and neck postures leading to forward head posture (fhp) which consequently alters the position of the mandible along with its functions, resulting in an increase tension in the masticatory muscles causing tmd. addicted smartphone users contribute to changes in craniocervical region which led to myogenic tmd in young teenagers. pain, tenderness in masticatory muscles and cervical muscle endurance are common clinical findings in patients with tmd; where muscle tenderness is reduced and cervical muscle endurance was found to have a shorter duration holding time when performing neck extensor endurance test due to higher fatigability of neck extensor muscles.

Eligibility criteria:
inclusion criteria: 1. subject's age range from 18 - 40 years. 2. both males and females will be recruited. 3. subjects diagnosed as myogenic tmd according to the presence of trigger points in masseter, temporalis, upper trapezius and c5-c6 articular pillars according to the myofascial diagnostic criteria that includes a taut band and hypersensitive spot 4. all subjects are heavy smartphones users, using the sas-sv, the cuffof value for males is 31 and for females is 33. 5. all subjects will have forward head posture assessed by cva less than 49.9 degrees. exclusion criteria: 1. history of head, neck or tmj trauma 2. patients who underwent orthodontic treatment 3. congenital, or acquired postural deformity 4. no previous neck or spinal or tmj surgery 5. subjects who are on anti-inflammatory or analgesic drugs for pain

Keywords: forward head posture smartphone
a study of xeloda (capecitabine) in breast cancer patients with central nervous system (cns) progression

Conditions: Breast Cancer

Summary: this single arm study will assess the efficacy of xeloda in the treatment of brain metastases in breast cancer patients with central nervous system (cns) progression after whole brain radiotherapy. patients will receive xeloda 1000mg/m2 po bid on days 1-14 of each 3 week cycle. the anticipated time on study treatment is until disease progression, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * female patients, \>=18 years of age; * breast cancer; * cns progression after radio-surgery + whole brain radiotherapy, or whole brain radiotherapy alone; * at least one measurable lesion; * ecog performance status 0-2. exclusion criteria: * prior systemic treatment of brain metastases; * prior disease progression while on xeloda treatment; * previous history of cancer (other than curatively treated basal and squamous cell cancer of the skin or in situ cancer of the cervix) in previous 5 years; * clinically significant cardiovascular disease.
use of provodine to protect hcw hands (aim ii.1)

Conditions: Infection

Summary: the investigators will assess whether applying provodine, an fda-approved hand hygiene product with a long duration of anti-microbial action, to healthcare workers' hands protects against self-contamination during the removal of personal protective equipment (gloves, gowns, etc).

we will perform a two-armed pilot test among 40 front-line healthcare workers (nurses, doctors, respiratory therapists, etc) at the university of iowa hospitals and clinics. participants will serve as their own controls. first, participants will perform hand hygiene with alcohol-based hand rub as they normally would in clinical practice then don ppe. we, the research team, will contaminate participating healthcare workers' (hcw) ppe with either bacteriophage ms2 (twenty participants) or s. marcescens atcc 14756 (twenty participants). ms2 preparation and propagation and s. marcescens culture suspensions will each be performed as previously described. the ms2 bacteriophage will be suspended in 0.01 m phosphate-buffered saline and each ppe site will be contaminated with 10\^5 plaque-forming units (pfu) of ms2 in 5 drops of 5 μl each. aliquots of 3 ml of s. marcescens broth suspension (yielding bacterial titers of \~1 x 10\^9 cfu/ml) will be applied to each ppe site. participants will then doff ppe using the centers for disease control's (cdc) recommended protocol. we will sample their hands using the bag broth method. a research assistant will monitor participants as they wash their hands with soap and water then rinse their hands with 70% ethanol. participants will then apply provodinetm to their hands and put on (don) fresh ppe. we will repeat the contamination, doffing, and sampling procedure. for ms2 recovery, we will assay the eluent using the most probable number (mpn) enrichment infectivity assay. for s. marcescens recovery, we will dilute the eluent, plate it, incubate the plates, and count the colonies as described.

Eligibility criteria:
inclusion criteria: * subjects must be uihc healthcare workers (doctors, nurses, etc.) exclusion criteria: * known skin sensitivity to povidone iodine or provodine (tm)

Keywords: hand hygiene healthcare worker self-contamination
prehabilitation for stage iiic-iv ovarian, fallopian tube, or primary peritoneal cancer patients

Conditions: Advanced Ovarian Carcinoma; Stage IIIC Fallopian Tube Cancer AJCC V8; Stage IIIC Ovarian Cancer AJCC V8; Stage IIIC Primary Peritoneal Cancer AJCC V8; Stage IV Fallopian Tube Cancer AJCC V8; Stage IV Ovarian Cancer AJCC V8; Stage IV Primary Peritoneal Cancer AJCC V8

Summary: this clinical trial evaluates whether a prehabilitation program started at the time of neoadjuvant chemotherapy will affect surgical recovery in patients with stage iiic-iv ovarian, fallopian tube, or primary peritoneal cancer. a prehabilitation program may improve the quality of life after surgery for patients with ovarian, fallopian tube, or primary peritoneal cancer.

primary objectives: i. to evaluate the baseline difference in objective frailty measurements in patients with advanced ovarian cancer clinically deemed acceptable for primary surgery versus neoadjuvant chemotherapy. ii. to evaluate level of adherence and retention of patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy with a prehabilitation program. exploratory objective: i. will examine longitudinal trends and variability in function by the short physical performance battery (sppb) over time and in response to the intervention. outline: patients are assigned to 1 of 3 cohorts. cohort 1: patients undergoing primary surgical intervention complete surveys, undergo computed tomography (ct), and undergo collection of blood samples at baseline. cohort 2: patients undergoing neoadjuvant chemotherapy complete physical activity for 30 minutes per day 3 times a week. patients receive nutritional supplement drink up to 4.5 times daily, and complete resilient living program in-person or remotely over 60 minutes. patients also undergo ct scans throughout the trial. cohort 3: patients undergoing neoadjuvant chemotherapy complete physical activity remotely for 30 minutes per day 3 times a week. patients receive nutritional supplement drink up to 4.5 times daily. patients also undergo health coaching remotely for 60 minutes weekly, complete resilient living program remotely over 60 minutes, and may wear a fitbit throughout the study.

Eligibility criteria:
inclusion criteria: * age \>= 18 years old * diagnosed with epithelial ovarian, fallopian tube, or primary peritoneal cancer based on imaging and physician diagnosis * suspected stage iiic or iv disease based on clinician staging and imaging * curative intent treatment with platinum-based chemotherapy * planned surgical intervention at some point during treatment course * ability to read english * no diagnosed severe cognitive impairment * ability to provide consent * ability to utilize technology to watch online modules for the resilient living program exclusion criteria: * hemiplegia or paraplegia * current pregnancy
efficacy and safety study of octafibrin for on-demand treatment of acute bleeding and to prevent bleeding during and after surgery

Conditions: Congenital Fibrinogen Deficiency

Summary: the purpose of the study is to assess the efficacy and safety of octafibrin for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiency.


Eligibility criteria:
inclusion criteria: * aged ≥12 years (only 18 and above in russia) * documented diagnosis of congenital fibrinogen deficiency, expected to require on-demand treatment for bleeding or surgical prophylaxis: * fibrinogen deficiency manifested as afibrinogenaemia or severe hypofibrinogenaemia. * historical plasma fibrinogen activity of \<50 mg/dl or levels below the limit of detection of the local assay method. * expected to have an acute bleeding episode (spontaneous or after trauma) or planning to undergo elective surgery. * informed consent signed by the subject or legal guardian. exclusion criteria: * life expectancy \<6 months. * bleeding disorder other than congenital fibrinogen deficiency, including dysfibrinogenaemia. * prophylactic treatment with a fibrinogen concentrate. treatment with: * any fibrinogen concentrate or other fibrinogen-containing blood product within 2 weeks prior to start of treatment for the bleeding episode or surgery. * any coagulation-active drug (i.e., non-steroidal anti-inflammatory drugs, warfarin, coumarin derivatives, platelet aggregation inhibitors) within 1 week prior to start of treatment for the bleeding episode or surgery, or as a planned or expected medication during the time period from day 1 until 24 hours (i.e., 1 day) after the last octafibrin infusion. presence or history of: * hypersensitivity to study medication. * deep vein thrombosis or pulmonary embolism within 1 year prior to start of treatment for the bleeding episode or surgery. * arterial thrombosis within 1 year prior to start of treatment for the bleeding episode or surgery * hypersensitivity to human plasma proteins. * oesophageal varicose bleeding. * end-stage liver disease (i.e., child-pugh score b or c). pregnant women within the first 20 weeks of gestation. currently breast-feeding. known positive hiv infection with a viral load \>200 particles/μl or \>400,000 copies/ml. polytrauma 1 year prior to start of treatment for the bleeding episode or surgery. diagnosis or suspicion of a neutralizing anti-fibrinogen inhibitor currently or any time in the past. acute or chronic medical condition which may, in the opinion of investigator, affect the conduct of the study, including * subjects receiving immune-modulating drugs (other than anti-retroviral chemotherapy) such as alpha-interferon, prednisone (equivalent to \>10 mg/day), or similar drugs at study start. * subjects having evidence or a history (within the previous 12 months) of abuse of any licit or illicit drug substance. participation in another interventional clinical study currently or during the past 4 weeks.
a study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma who received at least 3 prior lines of therapy including proteasome inhibitor (pi), immunomodulatory drug (imid), and cluster of differentiation 38 (cd38) monoclonal antibody treatment

Conditions: Multiple Myeloma

Summary: the purpose of this study is to assess the safety and clinical response including overall response rate (orr) of real-life standard-of-care (soc) treatments under routine clinical practice, over a 24-month period, in patients with relapsed/refractory multiple myeloma (rrmm).


Eligibility criteria:
inclusion criteria: * have a documented diagnosis of multiple myeloma according to international myeloma working group (imwg) diagnostic criteria * received at least 3 prior lines of therapy or are double refractory to a proteasome inhibitor (pi) and an immunomodulatory agent (imid) (induction with or without hematopoietic stem cell transplant and with or without maintenance therapy is considered a single regimen). patients will have undergone at least 1 complete cycle of treatment for each regimen (unless progressive disease was the best response) * must have documented evidence of progressive disease based on study physician's determination of response by the imwg response criteria on or after the last regimen. patients with documented evidence of progressive disease within the previous 6 months and who are refractory or nonresponsive to their most recent line of treatment afterwards are also eligible * have an eastern cooperative oncology group (ecog) performance status grade of 0 or 1 * must not be pregnant or must not plan to become pregnant within the study period
social participation after childhood craniopharyngioma

Conditions: Children With a Craniopharyngioma

Summary: craniopharyngioma is a rare, benign central nervous system tumor, which may be a source of multiple complications, from endocrinology to vision, neurology and neurocognitive functions. this morbidity can lead to reduced participation in life activities, as described in the international classification of functioning, disability, and health (icf). the primary objective of this study is to measure participation in life activities in a population of children affected by childhood craniopharyngioma, using the assessement of life habits questionnaire (life-h questionnaire), validated as a social participation measurement tool in various pediatric disabilities.


Eligibility criteria:
inclusion criteria: * children with a craniopharyngioma exclusion criteria: * none

Keywords: craniopharyngioma children social participation life-h questionnaire
assessment of new molecular imaging strategies for prostate cancer

Conditions: Prostate Cancer

Summary: in this study 30 men, with advanced metastatic castration-resistant prostate cancer (crpc) planned to have hormonal treatment, will undergo conventional imaging and functional imaging prior to treatment and post treatment to determine if changes in imaging results will be prognostic of outcome. patients will have a clinical follow-up every 3 months post randomization for one year and followed for survival at years 2 and 3.

in this study 30 men, with advanced metastatic crpc intended to have abiraterone acetate or enzalutamide hormonal treatment will undergo conventional imaging including a 99mtc-methyl diphosphonate (mdp) bone scan and computed tomography (ct) of the abdomen and pelvis, and functional imaging with 18f-fluorodeoxyglucose (fdg) pet-ct and 2-(3-(1-carboxy-5-\[(6-\[18f\]fluoro-pyridine-3-carbonyl)-amino\]-pentyl)-ureido)-pentanedioic acid (18f-dcfpyl) pet-ct one to four weeks prior to hormonal treatment and approximately 10 weeks post hormonal treatment. prostate specific antigen (psa) will also be obtained at baseline and every three months in the first year. baseline imaging of disease and changes between baseline and follow-up imaging on 18f-fdg pet-ct and 18f-dcfpyl pet-ct will be compared with standard of care imaging (99mtc-mdp bone scan and ct of the abdomen/pelvis) as well as with clinical evaluation including response to therapy and progression of disease. this information could be used by clinicians to guide androgen receptor (ar) - targeted therapy. patients will have a clinical follow-up every 3 months post randomization for one year and will be followed for survival at years 2 and 3.

Eligibility criteria:
inclusion criteria: 1. objectively documented metastatic prostate cancer progression with either of the following: * at least one rising psa over a minimum of one week interval within six weeks of study registration, or * radiographic progression in soft tissue and/or bone within six weeks of study registration 2. ongoing androgen deprivation therapy with serum testosterone \<50 ng/dl (\<1.7 nmol/l). 3. planned to start abiraterone acetate or enzalutamide. exclusion criteria: 1. age \< 18 years. 2. eastern cooperative oncology group (ecog) performance status \>2. 3. planned to receive palliative radiotherapy within the next 12 weeks. 4. hemoglobin \< 90 g/l independent of transfusion. 5. platelet count \< 50 x 10\^9 / l. 6. serum albumin \< 30 g/l. 7. serum creatinine \> 1.5 x upper limit of normal (uln) or a calculated creatinine clearance \<30 l/min. 8. contraindications to fdg. 9. inability to lie supine for imaging with pet-ct. 10. inability to undergo ct due to known allergy to contrast. 11. inadequate hepatic function: (i) bilirubin \>1.5 x uln, and (ii) serum glutamic oxaloacetic transaminase (sgot) \>3 x uln 12. inability to complete the study or required follow-up

Keywords: castration-resistant molecular imaging abiraterone acetate enzalutamide metabolic response
pneumococcal vaccination for splenectomised thalassemia major patients in indonesia

Conditions: Thalassemia; Pneumococcal Infection

Summary: splenectomized thalassemia major subjects were provided with pcv pneumococcal vaccine (prevenar 13®) at the start of the trial, following which they were randomly assigned to 2 groups (zinc and placebo group). after 8 weeks, the subjects received ppv pneumococcal vaccine (pneumovax®). zinc syrup was provided to the zinc group at a dose of 1.5 mg/kg/day (maximum of 50 mg/day). pneumococcal igg examinations were conducted at the start of the trial and after 12 weeks.

this study is a single blinded randomised-control trial. splenectomized thalassemia major patient samples were provided with pcv pneumococcal vaccine (prevenar 13®) at the start of the trial, following which they were randomly assigned to 2 groups (zinc and placebo group). after 8 weeks, the subjects received ppv pneumococcal vaccine (pneumovax®). zinc syrup was provided to the zinc group at a dose of 1.5 mg/kg/day (maximum of 50 mg/day). placebo containing sucrose syrup of the same form, taste, consistency and color was given to the other group. everyone except the primary researcher are blinded to which of the treatment is placebo and which is actual zinc syrup. pneumococcal igg examinations were conducted at the start of the trial and after 12 weeks. sample size was measured using: n1=n2=n= {((zα+zβ) sd)/d}\^2 where n = number of subject za = degree of significance (5%), a = 5% zb = strength of study (80%). b = 20% sd = standard deviation d = meaningful difference between the two groups the measured sample size is 816, but due to limited patient total population sampling was used instead.

Eligibility criteria:
inclusion criteria: * splenectomised thalassemia patient exclusion criteria: * non-splenectomised thalassemia patient
effectiveness of a digital therapeutic on type 2 diabetes

Conditions: Type2 Diabetes

Summary: a clinical study evaluating a three month digitally delivered lifestyle change program in adults with type 2 diabetes. the farewell program (the "program") aims to reduce well-established biomarkers of cardiometabolic diseases, weight, and medications. the current study is designed to evaluate to what degree adults with type 2 diabetes engaged with the program can improve glycemic control and/or decrease medication needs.

the program aims to reduce well-established biomarkers of cardiometabolic diseases, weight, and medications. it includes meal planning tools, smart shopping lists, recipes curated by a physician, dietitian and chef educator, daily self-monitoring features with personalized weekly goals, bi-weekly live one-on-one health coaching and support from an online member community, and an educational curriculum. subjects in the program may receive support from other members of a care team (lifestyle medicine physician, chef educator, registered dietitian and/or psychologist/psychiatrist) as needed. the care team does not provide medical advice, nor replace traditional medical care. instead, the care team encourages behavior change by providing support and sharing its expertise. study participants will have access to the program for a twelve week period and will be asked to complete short health surveys at baseline and at the end of the study.

Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes exclusion criteria: * inability to understand, consent to, or comply with the study protocol for any reason, including inability to read or comprehend english. * does not have a smartphone (either an iphone or android phone)
effect of lorcaserin on cannabis withdrawal and self-administration

Conditions: Cannabis Use

Summary: in this study, the investigators are interested in testing how lorcaserin influences the effects of cannabis in a human laboratory model of cannabis use.

in order to improve treatment outcome for cannabis use disorder (cud), the investigators have developed a laboratory model to investigate the effects of potential treatment medications on cannabis withdrawal and on the subjective and reinforcing effects of cannabis in non treatment-seeking cannabis smokers. in this study, the investigators are interested in testing how lorcaserin influences the effects of cannabis in a human laboratory model of cannabis use.

Eligibility criteria:
inclusion criteria: * current cannabis use * able to give informed consent and perform study procedures * women practicing an effective form of birth control * english speaking exclusion criteria: * presence of any clinically significant medical diagnoses * history of heart disease and cardiac risk factors, severe chronic obstructive pulmonary disease, uncontrolled hypertension, or diabetes * current parole or probation * certain psychiatric diagnoses * current pregnancy or lactation
prevailing microorganisms causing neonatal sepsis in neonatal intensive care unit (prospective study)prevailing microorganisms causing neonatal sepsis in neonatal intensive care unit (prospective study)

Conditions: Neonatal SEPSIS

Summary: prevailing microorganisms causing neonatal sepsis in neonatal intensive care unit of assiut university children hospital methods prospective study conducted in the neonatal intensive care unit in assiut university children hospital.

sepsis remains a leading cause of death in the intensive care units and in all age groups worldwide.sepsis was defined as the host's immune response(systemic inflammatory response syndrome) to injury and/or infectious stimuli in the presence of a known(or strongly suspected) infection .early onset neonatal sepsis occurs in utero or might become infected when exposed to potentially pathogenic bacteria,viruses,or fungi during passage through the birth canal.

Eligibility criteria:
inclusion criteria: * both preterm and full term neonates * both early onset and late onset neonatal sepsis exclusion criteria: * genetic diseases immunocompromized neonates * neonates of diabetic mothers * neonates of hiv mothers